Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Active, not recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1/2a dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed or refractory acute myeloid leukemia to determine the safety, tolerability, PK and preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD). Phase 2a will consist of up to 3 dose levels (high, medium, and low) of which subjects with FLT3 mutations will randomly be assigned.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
• Treatments: FF-10101

Criteria

Subjects who are able and willing to give written informed consent

• Documented primary or secondary AML, as defined by the WHO criteria (2008), by histopathology refractory to previous induction chemotherapy and/or relapsed after achieving remission with a prior chemotherapy and who are not candidates for other available therapy likely to confer clinical benefit.

• For Phase 2a only: in addition to inclusion criteria 2 above, patients must have a FLT3 mutation of any type

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

• In the absence of rapidly progressing disease, the interval from prior treatment to time of FF-10101-01 administration should be at least 14 days for cytotoxic agents other than hydroxyurea, at least 5 half-lives for non-cytotoxic agents, and 14 days for monoclonal antibody therapies. Hydroxyurea may be continued for a maximum of 14 days from the start of FF-10101-01 dosing, through Cycle 1 Day 14, with a maximal dose of 5 grams/day

• Persistent chronic clinically significant toxicities from prior chemotherapy or surgery must be ≤Grade 2

• If subject has had a hematopoietic stem cell transplant, subject must be ≥60 days post-transplant with no clinically significant GVHD requiring systemic therapy

• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤3 times the upper limit of normal and total bilirubin of ≤1.5x the upper limit of normal. If total bilirubin is equal to or exceeds 1.5x the upper limit of normal, the subject can still be included if direct bilirubin is ≤1.5x the upper limit of normal

• Calculated creatinine clearance of ≥60 mL/min

• Female subjects of childbearing potential and sexually mature male subjects must agree to use a medically accepted method of contraception other than an oral contraceptive for the duration of the study.

Exclusion Criteria:

• Subjects diagnosed with acute promyelocytic leukemia

• Subjects with Bcr-Abl positive leukemia (chronic myelogenous leukemia in blast crisis)

• Subjects with clinically active CNS leukemia

• Subjects with major surgery within 28 days prior to the first administration of FF-10101-01

• Subjects with radiation therapy within 28 days prior to the first administration of FF-10101-01

• Subjects with active malignant disease requiring therapy other than AML or myelodysplastic syndrome with transformation into AML

• Subjects with an active uncontrolled infection

• Subjects with a medical condition, serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the subject's safety as a study subject, or that could interfere with the study objectives

• Subjects known to have human immunodeficiency virus infection, or who have active hepatitis B or C infection as determined by serological testing

• Subjects with congestive heart failure, New York Heart Association (NYHA) Class 3 or 4, or subjects with a past history of congestive heart failure NYHA Class 3 or 4 and in whom echocardiogram or multiple gate acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a LVEF <40%

• Female subjects who are pregnant or breast feeding

• Subjects on 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or other drugs known to have muscle toxicity

• Subjects taking strong inhibitors of CYP3A4 will be excluded from the study unless therapeutic substitution is possible

• Subjects taking strong inducers of CYP3A4 will be excluded from the study unless therapeutic substitution is possible

• Use of systemic immunosuppressive agents within 14 days prior to first dose of FF-10101

• Subjects taking drugs known to cause Torsades de Pointes will be excluded from the study unless therapeutic substitution is possible

• Subjects known to have long QT syndrome

• Subjects with mean QTcF values following 3 ECGs conducted 5 minutes apart of >470 msec